| Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis JN Priantti, M Vilbert, T Madeira, FCA Moraes, ECK Hein, A Saeed, ... Cancers 15 (15), 3754, 2023 | 11 | 2023 |
| Cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone for HR-positive, HER-2-negative early breast cancer: meta-analysis of phase III … FCA Moraes, G de Oliveira Almeida, VFC Alves, JN Priantti, GC Gomes, ... Journal of Personalized Medicine 14 (5), 464, 2024 | 5 | 2024 |
| Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: a systematic review and meta-analysis JN Priantti, M Vilbert, FCA de Moraes, T Madeira, EM de Lima Santiago, ... Cancers 16 (14), 2024 | 1 | 2024 |
| Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis JN Priantti, NMV Rodrigues, FCA de Moraes, AG da Costa, DL Jezini, ... Endocrine, 1-9, 2024 | 1 | 2024 |
| Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma. M Vilbert, JN Priantti, T Madeira, FCA Moraes, A Tojjari, IH Sahin, ... Journal of Clinical Oncology 42 (3_suppl), 366-366, 2024 | 1 | 2024 |
| 1098P Anti-PD1-based neoadjuvant therapy in resectable stage III or IV melanoma patients: A systematic review and meta-analysis TM Madeira, FCA Moraes, JN Priantti, EM de Lima Santiago, MF Ribeiro, ... Annals of Oncology 34, S661, 2023 | 1 | 2023 |
| 1365P Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: A systematic review and meta-analysis JN Priantti, FCA Moraes, TM Madeira, EM de Lima Santiago, MS Vilbert Annals of Oncology 34, S784, 2023 | 1 | 2023 |
| Efficacy and Safety of Anti-EGFR Therapy Rechallenge in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis FCA de Moraes, ALS de Oliveira Rodrigues, JN Priantti, ... Journal of Gastrointestinal Cancer 56 (1), 1-12, 2025 | | 2025 |
| Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single … JN Priantti, Y Fujiwara, FC Aquino de Moraes, I Michelon, C Castro, ... JCO Precision Oncology 8, e2400331, 2024 | | 2024 |
| Antibody–drug conjugates in patients with advanced/metastatic HER2-low-expressing breast cancer: a systematic review and meta-analysis I Michelon, MI Dacoregio, M Vilbert, J Priantti, CE do Rego Castro, L Vian, ... Therapeutic Advances in Medical Oncology 16, 17588359241297079, 2024 | | 2024 |
| Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis FCA Moraes, M Vilbert, VFC Alves, G de Oliveira Almeida, JN Priantti, ... International Journal of Molecular Sciences 24 (24), 17582, 2023 | | 2023 |
| 281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast … VFC Alves, FCA Moraes, GDC Gomes, GDO Almeida, S Carnevalli, ... Annals of Oncology 34, S296, 2023 | | 2023 |
| Efficacy and safety of BRAF/MEK inhibitor rechallenge in patients with advanced melanoma: Systematic review and meta-analysis. JN Priantti, M Vilbert, T Madeira, FCA Moraes, EC Koch Hein, ... Journal of Clinical Oncology 41 (16_suppl), e21535-e21535, 2023 | | 2023 |
| Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis. T Madeira, M Vilbert, JN Priantti, FCA Moraes, EC Koch Hein, MF Ribeiro, ... Journal of Clinical Oncology 41 (16_suppl), e21542-e21542, 2023 | | 2023 |
| Análise molecular e genética complementar na investigação dos nódulos de tireoide: uma revisão integrativa da literatura JN Priantti, NMV Rodrigues, MC Cavalcante, DL Jezini, MIO Heckmann Revista do Hospital Universitário Getúlio Vargas 22 (1), 2023 | | 2023 |
| Priantti, JN1; Rodrigues, NMV1; Cavalcante, M1; Jezini, DL2; Heckmann, MIO3 JN Priantti | | |
